Table 3. Univariate and multivariate Cox proportional hazards regression model of preoperative clinical and imaging variables predicting biochemical recurrence.
| Covariate | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age, years | 0.98 (0.94–1.02) | 0.3 | - | - |
| BMI | 0.99 (0.92–1.07) | 0.8 | - | - |
| Preoperative PSA, ng/ml | 1.05 (1.02–1.07) | <0.0001 | 1.04 (1.01–1.07) | 0.01 |
| Race | ||||
| White | 1 | - | - | - |
| Black | 0.89 (0.35–1.92) | 0.8 | - | - |
| Other | 1.35 (0.46–3.23) | 0.6 | - | - |
| Clinical stage | 2.87 (1.37–5.61) | 0.007 | 1.38 (0.63–2.90) | 0.4 |
| Biopsy Gleason score | 3.76 (2.27–6.40) | <0.0001 | 2.35 (1.37–4.14) | 0.002 |
| MRI prostate volume, cc | 0.98 (0.96–1.00) | 0.06 | 0.98 (0.96–1.00) | 0.08 |
| MRI lesions, no | 0.80 (0.59–1.07) | 0.1 | 0.93 (0.68–1.26) | 0.7 |
| MP—MRI suspicion score | 3.49 (2.02–6.39) | <0.0001 | 1.97 (1.09–3.73) | 0.02 |
| mECE | 4.34 (2.27–8.72) | <0.0001 | 2.10 (1.05–4.40) | 0.04 |
| mSVI | 1.85 (0.30–6.05) | 0.4 | - | - |
BMI = body mass index; CI = confidence interval; HR = hazard ratio; PSA = prostate-specific antigen; MP-MRI = multiparametric magnetic resonance imaging; MRI = magnetic resonance imaging. Statistical significance denoted by bold face.